Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy

Sponsor
Shanghai Minimally Invasive Surgery Center
Study ID
NCT05111860
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab+mFOLFOX6 — DRUG
    Bevacizumab 5mg/kg d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles

Study Details

Prospectively Investigate the effectiveness and safety of neoadjuvant Bevacizumab + chemotherapy (mFOLFOX6) combined with short-course radiotherapy (25Gy/5Fx) for RAS mutant-type locally advanced rectal cancer

Key Dates

First listed
Nov 8, 2021
Start date
Nov 1, 2022
Status verified
Mar 2024
Primary completion
Aug 1, 2024
Completion
Aug 1, 2025

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Group 1

Primary Outcome Measure

Peri-operative complications [ Time Frame: From the start of treatment to 3 months after surgery ]

Central Contacts

Related Studies